How to Navigate the Increasingly Stormy Waters of Accessing US Managed Markets

The US reimbursement landscape for prescription drugs has been shifting rapidly over the last few years. Some of the major US access trends that have accelerated include: Payers increasing volume control over prescribed therapies, tightening formularies, and utilization management As the site-of-care landscape is consolidating, provider groups are incentivized to shift away from volume to … Continued

Real World Evidence Marches Forward in Drug Development

The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm on real-world evidence (RWE) and its adoption in the drug development process. While the collection of real-world data (RWD) and use of RWE is not new, they are now poised to have a profound impact on our industry. Today, it … Continued

1 of 1
Back to top
Powered by GlobalLink OneLink Software